Gina Vaccaro

Associate Professor

  • 389 Citations
  • 9 h-Index
20072019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Gina Vaccaro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 23 Similar Profiles
Esophageal Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoadjuvant Therapy Medicine & Life Sciences
Chemoradiotherapy Medicine & Life Sciences
Hepatocellular Carcinoma Medicine & Life Sciences
Adenocarcinoma Medicine & Life Sciences
Esophagectomy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2007 2019

  • 389 Citations
  • 9 h-Index
  • 18 Article
  • 2 Review article

A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer

Kearney, M. R., Chen, E. Y., Vaccaro, G., Strother, J., Burt, A., Todd, K., Donovan, J., Kampa-Schittenhelm, K. M. & Lopez, C., Jan 1 2019, In : Anticancer Research. 39, 1, p. 245-252 8 p.

Research output: Contribution to journalArticle

irinotecan
Colorectal Neoplasms
oxaliplatin
Neutropenia
Combination Drug Therapy
1 Citation (Scopus)

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design

Moehler, M., Ryu, M. H., Dvorkin, M., Lee, K. W., Coşkun, H., Wong, R., Chung, H. C., Poltoratsky, A., Tsuji, A., Yen, C. J., Muntean, A. S., Le Sourd, S., Vaccaro, G., Overton, L., Boku, N., Wainberg, Z. A., Patel, M., Sharma, M., Xiong, H., Conti, I. & 2 others, Taieb, J. & Bang, Y. J., Feb 1 2019, In : Future Oncology. 15, 6, p. 567-577 11 p.

Research output: Contribution to journalArticle

Stomach Neoplasms
Esophagogastric Junction
Stomach
oxaliplatin
Maintenance
152 Citations (Scopus)

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

KEYNOTE-224 investigators, Jul 1 2018, In : The Lancet Oncology. 19, 7, p. 940-952 13 p.

Research output: Contribution to journalArticle

Hepatocellular Carcinoma
pembrolizumab
sorafenib
Therapeutics
Disease Progression
22 Citations (Scopus)

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Abou-Alfa, G. K., Qin, S., Ryoo, B. Y., Lu, S. N., Yen, C. J., Feng, Y. H., Lim, H. Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W. P., Chen, Z., Hubner, R. A., Meyer, T., Sun, W., Harding, J. J., Hollywood, E. M., Ma, J. & 7 others, Wan, P. J., Ly, M., Bomalaski, J., Johnston, A., Lin, C. C., Chao, Y. & Chen, L. T., Jun 1 2018, In : Annals of Oncology. 29, 6, p. 1402-1408 7 p.

Research output: Contribution to journalArticle

Arginine
Hepatocellular Carcinoma
Patient Care
Placebos
Survival

Small Bowel Adenocarcinoma

Chen, E. Y. & Vaccaro, G., Jan 1 2018, In : Clinics in Colon and Rectal Surgery. 31, 5, p. 267-277 11 p.

Research output: Contribution to journalArticle

Adenocarcinoma
Biliary Tract Neoplasms
Gastrointestinal Neoplasms
Delayed Diagnosis
Polyps